Senseonics Reports 91% Revenue Surge

By Ahmed Jameison • Tuesday, October 07 10:23 • Permanent Link

Senseonics Holdings, Inc. (NYSE American: SENS) has announced its preliminary unaudited revenue for the third quarter of 2025, revealing a significant increase to $8.1 million. This represents a notable 91% surge compared to the third quarter of 2024. The company attributes this growth to a remarkable 160% increase in new patient starts in the U.S. over the previous year.

The surge in new patient growth has been driven by increased investment in direct-to-consumer (DTC) marketing, resulting in the highest number of monthly new patient starts in the company’s history, particularly in September 2025. This growth is largely attributed to the increasing enthusiasm for Eversense 365, the world’s first and only year-long continuous glucose monitoring (CGM) system.

Additionally, Senseonics announced a reverse stock split of its outstanding shares of common stock at a ratio of one-for-twenty, which is expected to be effective on October 17, 2025. This move will reduce the number of shares of common stock from approximately 816 million shares to approximately 41 million shares.

Tim Goodnow, Ph.D., President and Chief Executive Officer of Senseonics, expressed excitement about the team’s strong performance in the quarter, crediting it to the increasing enthusiasm for Eversense 365 and the ongoing investments in DTC marketing campaigns.

The company's common stock will continue trading on the NYSE American under the symbol “SENS,” with the new CUSIP number 81727U303 following the reverse stock split.

Senseonics Holdings, Inc. is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the global diabetes community with differentiated, long-term implantable glucose management technology. Their CGM systems, Eversense 365 and Eversense E3, aim to provide continuous glucose monitoring for individuals with diabetes.

The preliminary unaudited financial results and other business metrics for the quarter ended September 30, 2025, have not been audited or reviewed by the company's independent registered public accounting firm. Therefore, these estimates should not be viewed as a substitute for the company's full interim or annual financial statements. As a result of these announcements, the company's shares have moved 22.03% on the market, and are now trading at a price of $0.565. If you want to know more, read the company's complete 8-K report here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.